Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (12)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2015

  1. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

    Cancer Letters, Vol. 351, Núm. 1, pp. 30-40

2011

  1. Tumor type influences the effectiveness of pleurodesis in malignant effusions

    Lung, Vol. 189, Núm. 2, pp. 151-155

2009

  1. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions

    European Journal of Internal Medicine, Vol. 20, Núm. 4, pp. 383-386

2008

  1. Prognostic significance of pleural fluid data in patients with malignant effusion

    European Journal of Internal Medicine, Vol. 19, Núm. 5, pp. 334-339

  2. Rentabilidad del estudio citológico del líquido pleural en el derrame maligno

    Anales de Medicina Interna, Vol. 25, Núm. 4, pp. 173-177

2006

  1. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions

    Supportive Care in Cancer, Vol. 14, Núm. 5, pp. 475-478

2005

  1. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions

    Clinical Biochemistry, Vol. 38, Núm. 11, pp. 1031-1033

2004

  1. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions

    Chest, Vol. 126, Núm. 6, pp. 1757-1763